This article summarized the latest R&D progress of dexmedetomidine hydrochloride, the Mechanism of Action for dexmedetomidine hydrochloride, and the drug target R&D trends for dexmedetomidine hydrochloride.

Syndax Pharmaceuticals has reported encouraging preliminary figures following a protocol-defined collective examination of the essential AUGMENT-101 study on revumenib, a front-runner in the class of menin inhibitors.

Determining the effectiveness, safety, and marketability of a drug requires validation through clinical trials.

Menin is an expression product of the tumorigenic gene MEN1 in multiple endocrine neoplasia.

This article summarized the latest R&D progress of dexchlorpheniramine maleate, the Mechanism of Action for dexchlorpheniramine maleate, and the drug target R&D trends for dexchlorpheniramine maleate.

SOLA Biosciences is set to share its promising preliminary proof-of-concept data for SOL-257, a specific gene therapy aimed at misfolded TDP-43 in ALS.

This article summarized the latest R&D progress of dermatan sulfate, the Mechanism of Action for dermatan sulfate, and the drug target R&D trends for dermatan sulfate.

Vertex Pharmaceuticals Incorporated presented extensive data related to the patients treated in sections A and B of their Phase 1/2 clinical assessment trial of VX-880.

This article summarized the latest R&D progress of darifenacin hydrobromide, the Mechanism of Action for darifenacin hydrobromide, and the drug target R&D trends for darifenacin hydrobromide.

Purple Biotech Ltd. shares clinical insights from its dose amplification segment of the Phase 1/2 trial of NT219.

The most commonly used efficacy endpoints in clinical trials of anti-tumor drugs are Overall Survival (OS), Objective Response Rate (ORR), and Progression Free Survival (PFS), among others.

Ocular Therapeutix has publicized the start of its premiere primary clinical trial to examine OTX-TKI, a proprietary axitinib intravitreal implant, for tackling wet age-related macular degeneration.